News & Updates

First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022

Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.

First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
27 Sep 2022
Are healthcare workers more stressed out during the COVID-19 pandemic?
Are healthcare workers more stressed out during the COVID-19 pandemic?
27 Sep 2022
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
27 Sep 2022
Better cardiovascular health wards off dementia in older adults
Better cardiovascular health wards off dementia in older adults
27 Sep 2022
Eczema in kids: Ciclosporin induces rapid response, methotrexate affords sustained disease control
Eczema in kids: Ciclosporin induces rapid response, methotrexate affords sustained disease control
27 Sep 2022

In the treatment of children with atopic eczema, ciclosporin is linked to a more rapid response while methotrexate (MTX) is associated with sustained disease control following discontinuation, a study has found.

Eczema in kids: Ciclosporin induces rapid response, methotrexate affords sustained disease control
27 Sep 2022
Antihypertensive dosing TIME does not affect CV outcomes
Antihypertensive dosing TIME does not affect CV outcomes
26 Sep 2022 byRoshini Claire Anthony

Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.

Antihypertensive dosing TIME does not affect CV outcomes
26 Sep 2022